Images List Premium Download Classic

Immunotherapy

Immunotherapy-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Viral targeting with knottins
The Regents Of The University Of California
April 19, 2018 - N°20180105802

The use of targeting knottin polypeptides provides a means of selectively infecting target cells presenting species bound by the knottins. The targeted viruses may be used as cytotoxic agents, for example, as oncolytic viral therapeutics. Alternatively, the knottin-targeted viruses may be used to transform target cells in a gene therapy or immunotherapy context. An effective retargeted measles virus directed to ...
Immune modulator for immunotherapy and vaccine formulation
Health Research, Inc.
April 19, 2018 - N°20180105562

A recombinant flagrp170 protein and pharmaceutical compositions comprising a flagrp170 protein and related molecules encoding same, and cells presenting such a protein are provided. The flagrp170 protein comprises an nf-κb-activating domain of flagellin and an atp-binding domain truncated grp170. The pharmaceutical compositions of the invention can be used for the treatment or prevention of cancer or infectious ...
Radiotracer derivatives of trimethoprim for diagnositc imaging
The Trustees Of The University Of Pennsylvania
April 19, 2018 - N°20180104365

The present invention provides radiolabeled trimethoprim which are useful in imaging tests such as pet scans. The compounds show robust bacterial uptake in vitro and identify infections from inflammation or tumor when administered to a subject. The compounds show rapid and sensitive detection of ec dhfr containing tumors from control tumors and background tissue. In one aspect, a compound having ...
Immunotherapy Patent Pack
Download 225+ patent application PDFs
Immunotherapy Patent Applications
Download 225+ Immunotherapy-related PDFs
For professional research & prior art discovery
inventor
  • 225+ full patent PDF documents of Immunotherapy-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Cd5 chimeric antigen receptor for adoptive t cell therapy
Baylor College Of Medicine
April 19, 2018 - N°20180104308

Embodiments of the disclosure include methods and compositions related to immunotherapy that targets cd5. In particular embodiments, immune cells engineered to comprise a chimeric antigen receptor (car) that targets cd5 are contemplated, and uses thereof. In particular embodiments, the immune cells expressing the car do not commit fratricide to any great extent against t cells that express cd5 and which ...
Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the ...
Feldan Bio Inc.
April 12, 2018 - N°20180100158

The present description relates to methods for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell. The methods involve contacting the cell with the polypeptide cargo in the presence of a peptide shuttle agent at a concentration sufficient to increase the polypeptide cargo's transduction efficiency. Also described here are parameters that ...
Costimulatory b7-h1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic ...
Mayo Foundation For Medical Education And Research
April 12, 2018 - N°20180100015

The invention features methods of diagnosis by assessing b7-h1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with b7-h1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of b7-h1.
Immunotherapy Patent Pack
Download 225+ patent application PDFs
Immunotherapy Patent Applications
Download 225+ Immunotherapy-related PDFs
For professional research & prior art discovery
inventor
  • 225+ full patent PDF documents of Immunotherapy-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4...
Sunesis Pharmaceuticals, Inc.
April 12, 2018 - N°20180098975

Methods of treating, preventing or managing cancer, including certain leukemias are disclosed. The methods encompass the administration of enantiomerically pure (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid. Also provided are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions ...
Composition and methods of genome editing of b-cells
Dana-farber Cancer Institute, Inc.
April 05, 2018 - N°20180094243

The present invention provides methods compositions and methods of preparing autologous b-cells that secrete a monoclonal of interest useful in immunotherapy.
Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
Regeneron Pharmaceuticals, Inc.
April 05, 2018 - N°20180094070

The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and/or safety of an allergen-specific immunotherapy (sit) regimen. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (il-4rα) antagonist ...
Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
Regeneron Pharmaceuticals, Inc.
April 05, 2018 - N°20180094069

The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and/or safety of an allergen-specific immunotherapy (sit) regimen. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (il-4rα) antagonist ...
Novel peptides and combination of peptides for use in immunotherapy against various tumors
Immatics Biotechnologies Gmbh
April 05, 2018 - N°20180094043

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated t-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor ...
Combination treatment of cancer comprising egfr/her2 inhibitors
March 29, 2018 - N°20180086744

Optionally in combination with radiotherapy, radio-immunotherapy and/or tumour resection by surgery, furthermore, the invention relates to corresponding medicaments and the preparation thereof.
Matrix-embedded tolerance-promoting adjuvants for subcutaneous immunotherapy
Luxembourg Institute Of Health
March 29, 2018 - N°20180085452

The present invention relates to compositions and methods for the application of tolerance-promoting adjuvants embedded in alum-, microcrystalline tyrosine-, or hydrogel-based formulations for allergen- or autoantigen-specific immunotherapy.
Immunotherapy Patent Pack
Download 225+ patent application PDFs
Immunotherapy Patent Applications
Download 225+ Immunotherapy-related PDFs
For professional research & prior art discovery
inventor
  • 225+ full patent PDF documents of Immunotherapy-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Systems and methods for point/center-of-care immunotherapy
Miltenyi Biotec Gmbh
March 22, 2018 - N°20180080049

A cell modification device, comprising a centrifugation chamber with at least one cell modifying surface with a normal vector having an angle of 135−45° to the rotational axis of the centrifugation chamber, wherein the centrifugation chamber comprises at least one input/output port and the cells to be modified are immobilized at the cell modifying surfaces by the rotation ...
Combination immunotherapy for small cell lung cancer
H. Lee Moffitt Cancer Center And Research Institute, Inc.
March 22, 2018 - N°20180078628

A method is disclosed for treating small cell lung cancer (sclc) in a subject that involves administering to the subject a therapeutically effective amount of dendritic cells engineered to overexpress p53. In some embodiments, the method further involves administering to the subject a therapeutically effective amount of all-trans-retinoic acid (atra). The method can also involve administering to the subject a ...
Methods of cancer treatment using activated t cells
Syz Cell Therapy Co.
March 22, 2018 - N°20180078624

Provided is a method of treating a cancer in an individual using activated t cells or pbmcs induced by antigen presenting cells (such as dendritic cells) loaded with a plurality of tumor antigen peptides. The method may further comprise administration of the antigen presenting cells loaded with the plurality of tumor antigen peptides to the individual. The methods may be ...
Method of detecting new immunogenic t cell epitopes and isolating new antigen-specific t cell receptors ...
Helmholtz Zentrum MÜnchen-deutsches Forschungszentrum FÜr Gesundheit Und
March 15, 2018 - N°20180073013

The present invention relates to the field of immunotherapy, in particular, to adoptive t cell therapy, t cell receptor (tcr) gene therapy and vaccination. The invention provides a method for preparing a nucleic acid encoding the tcr alpha chain construct (tra) and tcr beta chain construct (trb) of a tcr construct specific for an epitope from an antigen presented on ...
Tc-ptp inhibitors as apc activators for immunotherapy
The Royal Institution For The Advancement Of Learning / Mcgill University
March 15, 2018 - N°20180072763

The invention encompasses the novel class of compounds represented by the formula (i) below, which are inhibitors of the tc-ptp enzyme. The invention also encompasses pharmaceutical compositions which include the compounds shown above and methods of treating or preventing tc-ptp mediated diseases, including cancer, via their use in the activation of antigen-presenting cells, like dendritic cells, for applications in the ...
Silicon dioxide nanoparticles and the use thereof for vaccination
Merck Patent Gmbh
March 15, 2018 - N°20180071386

The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer. The invention also relates to a method for the targeting of antigens at antigen-presenting cells and for the activation of the immune system, where the efficiency of ...
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other ...
Immatics Biotechnologies Gmbh
March 08, 2018 - N°20180066032

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated t-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor ...
Class i mhc phosphopeptides for cancer immunotherapy and diagnosis
Agenus Inc.
March 08, 2018 - N°20180066017

A set of phosphorylated peptides are presented by hla a*0101, a*0201, a*0301, b*4402, b*2705, b*1402, and b*0702 on the surface of melanoma cells. They have the potential to (a) stimulate an immune response to the cancer, (b) to function as immunotherapeutics in adoptive t-cell therapy or as a vaccine, (c) to facilitate antibody recognition of the tumor boundaries in surgical ...
Loading